QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)

QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01031797

Enrollment

124

Registered

2009-12-15

Start date

2008-01-31

Completion date

2009-03-31

Last updated

2009-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SLE

Keywords

SLE, Disease activity score, QT dispersion

Brief summary

QT dispersion can be a useful, simple noninvasive method for the early detection of cardiac involvement in SLE patients with active disease. The investigators therefore recommend cardiovascular evaluation for every SLE patient with an SLEDAI higher than 10.

Detailed description

Objective: Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality. Although autopsy studies have documented that the heart is affected in most SLE patients, clinical manifestations occur in less than 10%. QT dispersion is a new parameter that can be used to assess homogeneity of cardiac repolarization and autonomic function. We compared the increase in QT dispersion in SLE patients with high disease activity and mild or moderate disease activity. Methods: One hundred twenty-four patients with SLE were enrolled in the study. Complete history and physical exam, ECG, echocardiography, exercise test and SLE disease activity index (SLEDAI) were recorded. Twenty patients were excluded on the basis of our exclusion criteria. The patients were divided to two groups based on SLEDAI: 54 in the high-score group (SLEDAI \>10) and 50 in the low-score group (SLEDAI \<10).

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* no administration of drugs that would potentially influence QT duration except hydroxychloroquine * no history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes * normal resting ECG and a good-quality ECG recording to measure the QT interval.

Exclusion criteria

* moderate or severe valve disease * atrial fibrillation and other ECG abnormalities * systolic left ventricular dysfunction (ejection fraction \<50% or left ventricular end diastolic dimension \>5.5 mm * unreliable identification of the end of the T wave in the ECG and * known presence of cardiac disease including hypertension, diabetes or coronary artery disease.

Design outcomes

Primary

Measure	Time frame
QT dispersion	—

Countries

Iran

Outcome results